The impact of the mainstreaming addiction treatment act and associated legislative action on pharmacy practice
The recent passage of the Mainstreaming Addiction Treatment (MAT) Act will expand access
to treatment for opioid use disorder (OUD) by eliminating prescriber registration …
to treatment for opioid use disorder (OUD) by eliminating prescriber registration …
Addressing buprenorphine bottlenecks in the context of MAT Act implementation: A shared responsibility
Medications for opioid use disorder (OUD) such as buprenorphine reduce overdose
mortality and other opioid related acute health events but have historically been highly …
mortality and other opioid related acute health events but have historically been highly …
Challenges of estimating the value of buprenorphine injectables
LS Nelson, J Perrone - JAMA Network Open, 2023 - jamanetwork.com
Opioid overdose is a leading preventable cause of death in the US and has contributed to
the decline in life expectancy. The mortality associated with opioid use disorder continues to …
the decline in life expectancy. The mortality associated with opioid use disorder continues to …
Independent community pharmacists' attitudes and intentions toward dispensing buprenorphine/naloxone for opioid use disorder
R Zalmai, LG Hill, LJ Loera, Q Mosgrove… - Journal of the American …, 2023 - Elsevier
Abstract Background Buprenorphine/naloxone (BUP/NX) for opioid use disorder (OUD) is
associated with positive health outcomes; however, challenges accessing prescribed …
associated with positive health outcomes; however, challenges accessing prescribed …
Mapping buprenorphine access at Philadelphia pharmacies
Objectives Buprenorphine is not reliably stocked in many pharmacies, and pharmacy-level
barriers may deter patients from opioid use disorder care. We surveyed all outpatient …
barriers may deter patients from opioid use disorder care. We surveyed all outpatient …
Unfilled prescriptions: Surveying patients' experiences with buprenorphine treatment in Massachusetts before and during the COVID‐19 pandemic
JA Rosansky, M Albanese, J Phillips… - … American Journal on …, 2023 - Wiley Online Library
Abstract Background and Objectives We explored potential challenges to accessing office‐
based opioid treatment (OBOT) with buprenorphine during the COVID‐19 pandemic …
based opioid treatment (OBOT) with buprenorphine during the COVID‐19 pandemic …
[HTML][HTML] Assessing suboxone access in community pharmacies: Secret shopper model
BA DiPaula, CE Cooke - Exploratory Research in Clinical and Social …, 2023 - Elsevier
Abstract Objective To assess whether Maryland community pharmacies had Suboxone
available for dispensing. Methods This cross-sectional study used a secret shopper model to …
available for dispensing. Methods This cross-sectional study used a secret shopper model to …
Descriptive study: the novel “full spectrum people-with-opioid-use-disorder care model”
Abstract Background People with Opioid Use Disorder (PWOUD) represent an underserved
and marginalized population for whom treatment gaps exist. Low-barrier programs like …
and marginalized population for whom treatment gaps exist. Low-barrier programs like …
Addressing buprenorphine supply barriers: A guidance commentary
The current supply-side constraints limiting buprenorphine availability at pharmacies may
reduce the potential impact of recent initiatives to improve medications for opioid use …
reduce the potential impact of recent initiatives to improve medications for opioid use …
[HTML][HTML] Legislative and regulatory barriers to pharmacies dispensing buprenorphine for OUD
DM Strickland, JT Baker - Journal of Opioid Management, 2023 - wmpllc.org
Introduction: Buprenorphine (BUP) is increasingly recognized and utilized as a valuable
medication for the treatment of opioid use disorder. This article focuses on the problem of …
medication for the treatment of opioid use disorder. This article focuses on the problem of …